Carbinoxamine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Carbinoxamine: From Allergic Rhinitis and Urticaria to Allergic Urticaria
One-Sentence Summary
Carbinoxamine is a first-generation H1 antihistamine, originally used for allergic and vasomotor rhinitis, allergic conjunctivitis, the common cold, urticaria and angioedema. The TxGNN model predicts it may be effective for allergic urticaria, but this overlaps heavily with an existing indication. There are currently 0 clinical trials and 0 publications in the compiled data supporting this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, common cold, allergic/vernal/papillary conjunctivitis, nasopharyngitis, familial dermatographia, urticaria, angioedema (the Singapore licence lists no indication text) |
| Predicted New Indication | Allergic urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, carbinoxamine is a first-generation H1 antihistamine. Its efficacy in allergic and histamine-mediated conditions is established, and mechanistically it may be applicable to allergic urticaria through H1 receptor blockade of histamine-driven wheal and flare.
Allergic urticaria is a subtype of urticaria, which is already among carbinoxamine's original indications. The high score is therefore plausible, but this is largely an overlap with an existing indication rather than true repurposing.
The other top predictions follow a similar pattern:
- Cold urticaria (score 99.96%): H1 antihistamines are standard first-line therapy for this class, but the evidence is indirect and not specific to carbinoxamine.
- Nasal cavity disease (99.88%) and pharyngitis (99.87%): these largely overlap with the labelled rhinitis, common cold and nasopharyngitis indications. The term "nasal cavity disease" is too broad to evaluate, and evidence for sore throat relief is weak.
- Lower-ranked predictions (acute laryngopharyngitis, recalcitrant atopic dermatitis, atopic IgE responsiveness, rosacea conjunctivitis, bronchial disease, headache disorder): the mechanistic fit is weak or speculative. Carbinoxamine's anticholinergic drying effects could even be unhelpful, for example by thickening airway secretions or worsening dry eye.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07964P | BECAME TABLET (Y S P Industries (M) Sdn Bhd) | Tablet (oral) | Not stated in the compiled data |
Safety Considerations
- Contraindications suggested by the knowledge graph (these come from model-level drug–disease links, not from package insert text): hypertension, epilepsy, peptic/gastric ulcer, kidney disease, liver disease, pancreatitis, gallbladder disease, hypothyroidism, inflammatory bowel disease, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, coronary artery disease, myocardial infarction, atherosclerosis, heart conduction disease, sudden cardiac arrest, ocular hypertension, hemoglobinopathy, respiratory failure and hypotensive disorder.
- Drug Interactions: The interaction query returned 100 records. The 20 shown in the compiled data include:
- Major: potassium chloride and potassium citrate.
- Moderate: anticholinergic agents (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, clidinium, propantheline, mepenzolate, methscopolamine), opioids and related agents (morphine, opium, loperamide, eluxadoline), cannabinoids (dronabinol, nabilone) and metoclopramide.
The package insert warnings and contraindications for the Singapore product have not been reviewed. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically plausible but largely duplicates an existing indication (urticaria). The compiled data contain no clinical trials or literature, so the evidence level is L4, and the Singapore package insert safety information has not been reviewed. None of the other nine predictions has data to support moving forward.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Singapore product (SIN07964P), downloaded from the HSA website
- Mechanism of action data (for example from DrugBank)
- Drug-specific clinical or literature evidence for allergic urticaria and cold urticaria
- Clarification of whether the prediction adds any value beyond the existing urticaria indication
- A review of the knowledge-graph contraindications against the package insert, particularly for cardiovascular disease, glaucoma and prostatic hyperplasia, together with the anticholinergic and sedative interaction burden
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.